HI
AKBA icon

Hudock Inc’s Akebia Therapeutics AKBA Stock Holding History

Hudock Inc’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-300
Closed -$2K – 722
2020
Q1 		$2K Hold
300
– – ﹤0.01% 542
2019
Q4 		$1K Sell
300
-300
-50% -$1.43K ﹤0.01% 633
2019
Q3 		$2K Buy
600
+250
+71% +$1.07K ﹤0.01% 589
2019
Q2 		$1K Buy
+350
New +$1.99K ﹤0.01% 637
2019
Q1 		– Sell
-300
Closed -$2.06K – 658
2018
Q4 		$1K Hold
300
– – ﹤0.01% 589
2018
Q3 		$2K Sell
300
-100
-25% -$894 ﹤0.01% 599
2018
Q2 		$3K Buy
+400
New +$4K ﹤0.01% 543

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Hudock Inc's AKBA Position: Q2 2020 in Review

Hudock Inc sold out of Akebia Therapeutics (AKBA) in Q2 2020, closing a stake of 300 shares — an estimated $2K sold.

Hudock Inc first reported a position in AKBA in Q2 2018 and held it in 7 quarters. The position peaked at $3K in Q2 2018. 189 funds tracked by Wall St. Rank hold AKBA as of Q2 2020.

  • Hudock Inc reported no remaining Akebia Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Hudock Inc sold 300 Akebia Therapeutics shares in Q2 2020, an estimated $2K.
  • Hudock Inc first reported a position in Akebia Therapeutics in Q2 2018 and held it in 7 quarters.
  • Hudock Inc's Akebia Therapeutics position peaked at $3K in Q2 2018.
  • 189 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2020.

Based on Hudock Inc's 13F filing for Q2 2020, filed 11 Aug 2020.